Mannitol

Excerpt

Mannitol is FDA-approved for the reduction of intracranial pressure associated with cerebral edema and the reduction of intraocular pressure. Mannitol is also administered via inhalation as adjunctive therapy in cystic fibrosis. Additionally, it promotes diuresis in acute kidney injury, aiding in the prevention or treatment of the oliguric phase and facilitating the excretion of toxic substances and metabolites. This activity discusses mannitol's mechanism of action, adverse event profile, monitoring parameters, administration guidelines, clinical toxicology considerations, pharmacokinetic aspects, contraindications, and relevant interactions. Equipping healthcare professionals with this knowledge allows them to tailor treatment plans, optimize dosing strategies, and effectively manage adverse reactions, enhancing outcomes for patients with conditions managed with mannitol therapy.